English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Atopic dermatitis is a chronic cutaneous pathology, which requires intensive skin care and pharmacological therapy; current available treatments still need urgent improvements, especially for long-term use and specific groups (e.g. children). Nanotechnology has contributed with innovative drug delivery systems and can offer effective targeted therapies. Study purposes were to prepare and to characterize hydrocortisone acetate-loaded polycaprolactone nanoparticles in terms of their physicochemical properties, encapsulation efficiency, in vitro drug release and in vivo safety studies of the used excipients in human subjects. Resultant nanoparticles had a mean size of 258.4 24.5 nm and polydispersity index of 0.084. Zeta potential was -4.39 0.62 mV and the efficiency encapsulation was 36.32 0.03 %. In addition, in vitro release studies demonstrated a prolonged release of drug from the nanoparticles over time. Moreover, preliminary safety studies indicated that the formulation was well tolerated. This study demonstrates that acetate hydrocortisone-loaded nanoparticles are stable systems that can lead to a prolonged release of the drug with promising results in terms of safety when applied to the human skin.

Hydrocortisone acetate-loaded PCL nanoparticles as an innovative dermatological therapy for atopic dermatitis